304 related articles for article (PubMed ID: 27897325)
1. The biomarker landscape in mycosis fungoides and Sézary syndrome.
Dulmage B; Geskin L; Guitart J; Akilov OE
Exp Dermatol; 2017 Aug; 26(8):668-676. PubMed ID: 27897325
[TBL] [Abstract][Full Text] [Related]
2. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
[TBL] [Abstract][Full Text] [Related]
3. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
[TBL] [Abstract][Full Text] [Related]
5. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
[TBL] [Abstract][Full Text] [Related]
6. The time for new biomarkers in mycosis fungoides/Sézary syndrome is here.
Ortiz-Romero PL
Br J Dermatol; 2021 Aug; 185(2):250-251. PubMed ID: 34096050
[No Abstract] [Full Text] [Related]
7. Mycosis Fungoides and Sézary Syndrome: An Update.
Larocca C; Kupper T
Hematol Oncol Clin North Am; 2019 Feb; 33(1):103-120. PubMed ID: 30497668
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides and Sézary syndrome - Review and outlook.
Latzka J; Trautinger F
J Dtsch Dermatol Ges; 2023 Apr; 21(4):386-391. PubMed ID: 36971307
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
10. CD30
Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
[No Abstract] [Full Text] [Related]
11. [Clinical characteristics of mycosis fungoides and Sézary syndrome].
Krc L; Dobesová J; Bucek M; Dusek J; Macák J; Galuszková D; Jurysek O
Vnitr Lek; 1997 May; 43(5):285-9. PubMed ID: 9601850
[TBL] [Abstract][Full Text] [Related]
12. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.
Yamashita T; Abbade LP; Marques ME; Marques SA
An Bras Dermatol; 2012; 87(6):817-28; quiz 829-30. PubMed ID: 23197199
[TBL] [Abstract][Full Text] [Related]
13. [Mycosis fungoides and Sézary syndrome, so-called cutaneous T-cell lymphoma].
Rupniewska ZM
Postepy Hig Med Dosw; 1982; 36(4):231-49. PubMed ID: 6764803
[No Abstract] [Full Text] [Related]
14. Genotyping of cutaneous T-cell lymphomas and pseudolymphomas.
Bignon YJ; Souteyrand P
Curr Probl Dermatol; 1990; 19():114-23. PubMed ID: 2404672
[No Abstract] [Full Text] [Related]
15. Mycosis fungoides and sezary syndrome: an update.
Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
[TBL] [Abstract][Full Text] [Related]
16. [Current therapeutic options in Mycosis fungoides and Sézary syndrome].
Albrecht JD; Nicolay JP
Hautarzt; 2022 Jan; 73(1):75-85. PubMed ID: 34988613
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis.
Stoll JR; Willner J; Oh Y; Pulitzer M; Moskowitz A; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1073-1090. PubMed ID: 33940098
[TBL] [Abstract][Full Text] [Related]
18. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
[TBL] [Abstract][Full Text] [Related]
19. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
Querfeld C; Zain J; Rosen ST
Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
[TBL] [Abstract][Full Text] [Related]
20. What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?
Akilov OE
Cells; 2023 Sep; 12(18):. PubMed ID: 37759543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
